

Life and health sciences

1
ANILING
aniling.com

Life and health science industries

 04/2014

We make Precision Medicine possible thanks to the Epigenomic Revolution

PROBLEM

New tools for genomic analysis will make precision medicine possible. These tools respond to the challenges of obtaining clinically reliable data that also record the relationship between our DNA and the environment.

SOLUTION

GEUS (Genomic and Epigenomic Unified Sequencing) is a solution that combines reactive agents and software to enable, for the first time, integrated analysis of the genome and the epigenome with a high degree of reliability. GEUS is capable of adapting to new processes and analytical instruments, opening the door to potential market expansion.

BUSINESS MODEL

Bringing the technology to the market, focusing, initially, on specific research segments and hospitals, before licensing the tool to the biggest enterprises in the sector.


COMPETITION

Other technologies are used to analyse the genome or the epigenome separately, which is why reliability is not achieved in a sufficiently effective manner and, therefore, their scope is limited.

MILESTONES

- March 2014 ● 1st finalist, BioEmprenedorXXI. 1st funding round: €150,000.
- March 2015 ● RETOS-Colaboración Mineco project (€1 million).
- July 2016 ● Second prototype. National patent phases.
- July 2017 ● Application of MVP with Hospital Clinic (early adopter).
- December 2017 ● Regulatory compliance and pre-production of GEUS Kit for Research.
- March 2018 ● Marketing launch of GEUS Kit for Research.

FINANCIAL PROJECTIONS AND FUNDING NEEDS



 €22,000 per month

€800,000 (€600,000 from private investors and a €200,000 ENISA/CIF participatory loan. For: (A) validation of the GEUS Kit for Research (benchmarking); and (B) regulatory compliance, production and market trial. Of these amounts, €110,000 is already committed.

aniling
accelerating epigenomics

CONTACT

Llorenç Coll Mulet
Ctra. de Can Ruti, Camí de les Escoles, s/n
08916 Badalona (Barcelona)
Tel. 935 543 050
lcoll@aniling.com

TEAM



Llorenç Coll
CEO



Miguel A. Peinado
CSO



Jaume Amat
Advisor



ASK THE ENTREPRENEUR

Llorenç Coll Mulet

What is the company's most significant risk and how will you tackle it?

By implementing the full potential of a disruptive technology on the market. Working with early adopters.

How do you see the company in 5 years' time?

Kits on the market. Implementation of new kits. Attractive enough to complete our portfolio of major players.


€25,000


€193,000



Company founded



Monthly burn rate



K invested by the team



External K raised